Biocooler

[Biocooler @Biocooler1]

@JackPrescottX @Jare92365776 Nope Abdera shut its doors a month ago. Auctioning off equipment now…https://t.co/NM1OpaXJHh

[Biocooler @Biocooler1]

@MysteriousMole1 @jesse_brodkin Yep totally agree. The biohacker/fitness community has already widely adopted low dose gray market Reta for body recomposition. Dosing rec starts at 1mg/wk typically ending up at 3-4 mg/wk - waaay below the doses used in this study.

[Biocooler @Biocooler1]

@bioinvestor24 @wa154lco $LLY Retatutride will eat $PFE/$mtsr lunch. Anecdotally I know many who have cut major fat on reta while preserving lean mass and very few have side effects (and none with vomiting/nausea) . Nobody cares about monthly dosing when you have that kind of weekly profile.

[Biocooler @Biocooler1]

@AdamSinger Agree. prioritizing lifting + tracking calories and protein is the GOAT for fat loss. Eat 10-12x your goal body weight in calories and aim for 40% of that to be from protein. The fat melts off, even in your 40s. GLP-1s make the diet part easier of course, but they are NOT req’d.

[Biocooler @Biocooler1]

@bioinvestor24 Agree. I think we’re reaching a tipping point where wkly tirz (and soon, reta) is seen as so effective, so tolerable, and so easy (a pen or 30g insulin syringe into belly feels like nothing) that the stigma of injections over orals will continue to erode fast.

[Biocooler @Biocooler1]

@bioinvestor24 Private companies will remain the lion’s share of deal value until we start to see IPOs again.

[Biocooler @Biocooler1]

@unusual_whales Wait until all these companies realize how much AI fakes data and information and presents it as factual. We are not there yet for AI to truly replace a lot of manual entry level grunt work, especially when it comes to research or anything requiring some level of interpretation.

[Biocooler @Biocooler1]

@VPrasadMDMPH When everyone is special, no one is.

[Biocooler @Biocooler1]

@princetongb @Pharmdca Yup, agree with this. They likely had a chance to partner injectable early but got too big for their britches with unrealistic value expectations as a late market entrant, and pharmas balked. This is what happens without anyone in C suite who is seasoned in BD.

[Biocooler @Biocooler1]

@Scooter0732 @Biotenic Well it is not a scale that makes sense if administered within a couple hours of baseline as mostly it asks questions about daily life - like sleep, appetite, ability to conduct daily activities. I am suspicious of any study claiming this scale has substantially changed in 2 hrs

[Biocooler @Biocooler1]

@Enezator

[Biocooler @Biocooler1]

@BillSimmons The only way this could have been better is if you had @Dameshek there saying “no pain, no pain” while Brandt did hanging ab crunches.

[Biocooler @Biocooler1]

@leadlagreport Keep looking for that black swan event. DeepSeek will not have the negative you think/hope it will. I am waiting for your total capitulation before I get worried that the top is near.

[Biocooler @Biocooler1]

@paras_biotech @Varro_Analytics Why would investors want to own companies that just create assets and sell them off before major value inflection points? Little opportunity for M&A (again since the companies are happy to let pharma pick off their lead assets one by one) turns US investors away from China.

[Biocooler @Biocooler1]

@bradloncar @JebKeiper The reality is pts are learning every day how to better manage incretin class tolerability issues, largely through the help of online support communities. The AE %s in an early clinical trial are somewhat irrelevant commercially, so long as they aren’t way out of line.

[Biocooler @Biocooler1]

@Sanctuary_Bio @BertrandBio Also given that apparently Centerview is the only advisor to represent all the targets.

[Biocooler @Biocooler1]

@ZbJohnson124 @PCM_bio Exactly. It is no longer a place where pharma wants to announce splashy deals because they want the bios to be cheaper. It’s only for the start of deal processes that might materialize later in the year.

[Biocooler @Biocooler1]

@7SkiesTech @GilaMonstrum I’d like to see LLY roll out a much better cash pay model for all doses. I think many patients would pay $100-200/mo to secure their monthly supply without ever dealing with the hassles of insurance, many of whom are dropping coverage or gouging employers who want to include it.

[Biocooler @Biocooler1]

@PersimmonTI This is my exact experience on Zepbound too. I thought I would be nauseous and therefore not want to eat, rather it’s more a total lack of cravings/snacking/evening hunger. I don’t think much about food except what I need to meet my (very low) calorie target. I love it.